Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QUC398
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
QUC398 is an investigational biological drug developed by Novartis for the treatment of knee osteoarthritis. It functions as an inhibitor of the enzyme ADAMTS5 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs 5), which is implicated in cartilage degradation associated with osteoarthritis. The drug was administered as a subcutaneous injection and evaluated in Phase II clinical trials to assess its efficacy in reducing pain and preserving cartilage in patients with symptomatic knee osteoarthritis. Despite demonstrating a favorable safety profile, development was discontinued after interim analysis showed insufficient effect on pain relief.
02
Targets
ADAMTS5 (A disintegrin and metalloproteinase with thrombospondin motifs 5)
Beyond the preview
Go deeper on QUC398.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QUC398.